The use of ultrasound to facilitate the delivery of genetic-based therapeutic strategies by Silcox, Christina, 1978-
THE USE OF ULTRASOUND TO FACILITATE THE DELIVERY
OF GENETIC-BASED THERAPEUTIC STRATEGIES
BY
CHRISTINA SILCOX
B.S., BIOMEDICAL ENGINEERING. BOSTON UNIVERSITY. 2000
Submitted to the Department of Electrical Engineering and Computer Science
in Partial Fulfillment of the Requirements for the Degree of
Master of Science
at the
Massachusetts Institute of Technology
September 2004
0 2004 Christina Silcox. All rights reserved.
The author hereby grants to MIT permission to reproduce and to distribute
publicly paper and electronic copies of this thesis document in whole or in part.
Signature of Author:
Department of Electrical Engineering









Distinguished Professor in HST
Mn.achusetts Institute of Technoloov
Accepted By:
Arthur C. Smitt
Graduate Committee Chairman A S'J$ ETTS NSTTUTF
OF TECHN0L OG
OCIWO
iC T 2 2004
LIBRARIES
The Use of Ultrasound to Facilitate the Delivery
of Genetic-Based Therapeutic Strategies
by
Christina Silcox
Submitted to the Department of Electrical Engineering and Computer Science on July 12,
2004 in Partial Fulfillment of the Requirements for the Degree of Master of Science
ABSTRACT
Gene therapy is the introduction of exogenous genes to a cell to "fool" the cell into
producing the coding protein. There are ongoing studies in cancer-killing gene therapies,
kidney cell regeneration and many genetic disorders such as cystic fibrosis and severe
combined immunodeficiency (SCID). However, it has been discovered that developing
the therapy is not enough. A method to deliver the drugs is equally important.
The objective of this work was to explore two potential uses of ultrasound for gene
delivery. The first is to determine if ultrasound-induced cavitation can be used to enhance
in vivo transfection of gene therapy. Second, to use non-invasive ultrasonic heating to
spatially control gene therapy expression in vivo after delivery.
In the first phase of this project, feasibility experiments were performed to show an
increase in transfection efficiency occurred when using microbubbles, ultrasound,
plasmid and genes compared to plasmid and genes alone. An ultrasound transducer was
then designed to optimize experimental conditions for invasive in vivo experiments
taking into consideration optimal transducer size, focal distance, and frequency. When
testing the transducer, a potential side effect to using ultrasound to increase transfection
was discovered.
In the second phase of exploration, the use of MRI-monitored ultrasound to induce
enhanced expression of luciferase after local injection of the gene construct Ad-HSP-Luc
was explored. Using a construct that includes an hsp promoter allows the activation of the
associated transgene only in areas that are subsequently heated after injection. Increased
luciferase expression was observed in areas that were exposed to ultrasonic heating.
It is hoped that the positive results of these preliminary experiments will eventually lead
to a clinical methodology where ultrasound-enhanced gene therapy transfection would be
followed with ultrasound-directed spatial control of gene expression.
Thesis Supervisor: Kullervo Hynynen
Title: Professor of Radiology, Harvard Medical School
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1. INTRODUCTION TO GENE THERAPY
1.1. WHAT IS GENE THERAPY?
Gene therapy is the introduction of exogenous DNA into a cell that then causes the
cell to produce a therapeutically beneficial protein. Although initially gene therapy
was thought best suited to cure inherited genetic diseases, technical difficulties such
as targeting specific cell types in vivo, regulating expression of the therapeutic genes,
and controlling vector immunogenicity (Nabel 2003) has shifted research focus to
acquired diseases such as cancer, cardiovascular disease and HIV. GeMCRIS
(http://www.gemcris.od.nih.gov), the NIH database listing all ongoing clinical trials
involving gene therapy, lists 442 of the 1005 current trials as cancer-related while
ongoing gene therapy studies in the cardiovascular field explore clinical problems
such as prevention of restenosis after angioplasty or stent implantation, prevention of
venous graft failures, and therapeutic angiogenesis (Gruchala et al. 2004).
1.2. HOW GENE THERAPY WORKS
1.2.1. DNA INCORPORATION
For gene therapy to be effective, the gene must be delivered past both the cell and
nuclear membranes into the cell nucleus. Once in the nucleus, the DNA segment can
be incorporated in one of three ways: incorporating randomly into the cell DNA,
cutting out and replacing a defective segment of the cell DNA, or remaining separate
in the nuclear material and using various enhancers and promoters to encourage
translation by the host cell messenger RNA. Incorporation into the cell DNA is
essential for stable expression of the therapeutic gene, a requirement in long-term
treatment of inherited genetic disorders. If the therapeutic gene remains separate from
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the host DNA, expression is lost over time. This property can be used to advantage in
the treatment of many acquired diseases, for example when using a "suicide gene" to
treat malignant tumors (Colosimo et al. 2000).
1.2.2. IN VIVO VERSUS IN VITRO
Gene therapy can be delivered to target cells by both in vitro and in vivo methods.
There are advantages and disadvantages to each method (Culver 1996). In vitro
delivery requires obtaining cells from the patient, delivering the gene therapy, and
implanting the cells back into the patient. This has the advantages of both high
efficiency, defined as the ratio of gene expression to DNA inputted, and selective
delivery of the therapeutic gene to the cell types desired to be transfected. The
significant limitation to the in vitro method is that the target cells must be removable
from the body. This generally limits in vitro gene delivery to hematopoietic,
endothelial, and tumor cells. In contrast, in vivo delivery does not require cells to be
removed from the body, but the delivery efficiency is generally much lower and the
methods developed to increase this efficiency have additional side effects. In
addition, selectively transfecting only certain cell types in vivo is challenging.
1.2.3. VIRAL VECTORS
Vectors were created to increase the efficiency of in vivo gene therapy. Modified
viruses are the most commonly used and most effective vectors. Viral vectors are
classified into categories based on the original viral type, for example retroviruses,
adenoviruses and adeno-associated viruses.
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Retroviruses, such Moloney Murine Leukemia Virus (MMLV), were the first viruses
modified into viral vectors (Guild et al. 1988; Miller 1992; Miller et al. 1993; Riviere
et al. 1995; Robbins et al. 1994) and are still the most common delivery vector used
(McTaggart and Al-Rubeai 2002; Andreadis et al. 1999). To make a viral vector the
virus is first disabled of its disease function and made incapable of replication. The
therapeutic gene desired for transfer is then grafted onto the stripped virus. Retroviral
vectors retain the ability to reverse transcribe into the target cells' DNA, thus
integrating into the host DNA and allowing the therapeutic gene to divide with the
cell (McTaggart and Al-Rubeai 2002). This property can be advantageously exploited
when treating disease states that require lifelong therapeutic effects but render
retroviruses inappropriate for disease states that only need temporary therapy.
Another disadvantage of using the majority of retroviral vectors is that only retroviral
vectors derived from the lentivirus subgroup can infect cells that divide slowly or that
are quiescent (Lewis and Emerman 1994; Federico 1999). The best-characterized
lentivirus for vector delivery is the HIV virus but patient acceptability may limit its
clinical use. Other concerns with retroviral vectors involve long-term side effects as
well as fears that the virus may mutate back into a replication-capable form or
integrate into an oncogene site and promote cancerous growth. This last fear has
heightened under the recent discovery that several children treated with a retrovirus-
delivered gene therapy agent have developed a leukemia-like disease (Hacein et al.
2003). Because of this, all human clinical studies involving gene therapy delivered
with a retrovirus in the US were halted early in 2003 (Stolberg 2002) and are
currently being reviewed on a case-by-case basis (Fox 2003). However, research has
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recently suggested that the adverse result in this case was due to an unlikely
coincidence particular to the type of promoter/gene sequence inserted and the location
of insertion (Dave et al. 2004; McCormack and Rabbitts 2004) and should not occur
with other therapeutic genes.
Adenoviruses are a class of viruses most commonly associated with causing upper
respiratory infections but can also cause pharyngitis, conjunctivitis, gastroenteritis
and pneumonia. Unlike retroviruses, these vectors do not integrate into the host cell
DNA, which causes the therapeutic function to be lost over time. Adenoviruses have
the ability to transfect a wide variety of cell types and can transfect non-dividing as
well dividing cell types. The smaller size of adenoviral vectors allow delivery in
higher titer volumes than retroviruses (1012 to 1013 viral particles/mL) (Volpers and
Kochanek 2004) and efficiency is high meaning large amounts of therapeutic protein
can be produced from a single injection. The biggest concern in using adenoviruses is
the danger demonstrated by the highly publicized death of Jesse Gelsinger in
September 1999, which was caused by an immune response to administration of the
adenoviral vector. Adenoviral vectors express low levels of viral antigens following
infection. This often stimulates an immune response to the infected cells and results
in a loss of therapeutic gene expression 1-2 weeks after injection (Yang and Wilson
1995; Yang et al. 1996). In the Gelsinger case, the amount of virus given to him
caused such an immense and immediate immune reaction that several of his organs
went into failure. Strict control over dosage and concurrent immunosuppressive
therapy can be used to control this side effect but may still ultimately limit adenoviral
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vector usefulness. So-called "second generation" and "gutless" adenoviruses are
currently in development to help solve these problems (Volpers and Kochanek 2004).
The adeno-associated virus (AAV) is not technically a virus but rather a symbiotic
organism found with adenoviruses. Because AAVs are not known to cause any
diseases in humans and no immune response is caused by the introduction of AAVs,
these vectors are considered very safe. The disadvantages of using AAV vectors are
mostly practical: the small size of the vector restricts the size of the therapeutic gene
that can be attached to less then 5.2kB and these vectors are very expensive to
produce. Also, recent research has found that AAV vectors integrate preferentially
into the gene-rich areas of the host chromosomes (Nakai et al. 2003). This means that
AAV vectors could potentially share some of the risks now being associated with
retroviruses, but since AAV vectors only integrate into cell chromosomes rarely, the
risk is much reduced.
As a means of incorporating the benefits of a range of viral vectors, chimeric vectors
are also under development. These vectors try to combine the desirable features of
two or more virus types to eliminate the undesirable effects (Robbins and Ghivizzani
1998; Caplen et al. 1999; Duisit et al. 1999).
1.2.4. NON-VIRAL VECTORS
Due to ongoing concerns about the safety of viral vectors, non-viral vectors have also
been explored: liposome transport, naked DNA injection, electroporation and
ultrasound among others. In the 1990s it was shown that naked plasmid DNA
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injection can induce gene expression in skeletal muscle (Wolff et al. 1990), liver
(Hickman et al. 1994), thyroid (Sikes et al. 1994), heart muscle (Ardehali et al.
1995), brain (Schwartz et al. 1996), and urological organs (Yoo et al. 1999). Although
naked DNA injection usually does not cause integration into the chromosome,
expression can persist for several months (Acsadi et al. 1991; Manthorpe et al. 1993).
However, transfection efficiencies are much lower than with viral vector. By
transporting genes on liposomes, the negative charge of the DNA is decreased,
facilitating interactions with cell membranes and increasing transfection efficiency
(although not up to viral vector levels). Liposomes also protect the DNA from
damage, cause no immunogenic response and can be designed to target specific cells
and tissues. Electroporation, the application of short and intense DC electric pulses
that can reversibly increase cell membrane permeability (Mir et al. 1988), is an
effective tool for delivering gene therapy in vitro but is limited in vivo. Ultrasound,
however, has the advantage of being able to be used in conjunction with other vectors
and can also direct the gene therapy to target tissues/cells.
2. INTRODUCTION TO ULTRASOUND
2.1. DEFINING ULTRASOUND
Sound is a form of mechanical vibrational energy; it moves and propagates by
vibrating particles into compressions and expansions, resulting in a mechanical wave.
By definition any sound wave over 20,000 Hz (the upper range of human hearing) is
considered ultrasound. Application of ultrasound has been known to bring about
changes in tissue structure and biological processes given high enough intensities
since the late 1920s (Wood 1927; Harvey 1928). Early investigations suggested the
11
possibility of ultrasound energy inducing a therapeutic effect in biological tissue
(Horvath 1944) by mechanisms that are now divided generally into thermal (Barnett
1992) and non-thermal/mechanical effects (Dunn 1978; Barnett et al. 1994; Barnett
et al. 1997). Research into the application of ultrasound has been conducted for such
varied disciplines such as neurosurgery (Fry et al. 1954), ophthalmology (Lizzi et al.
1978), urology (Gelet et al. 1993; Foster et al. 1993), oncology (Chapelon et al. 1992;
Yang et al. 1991; Prat et al. 1995) and physiopathology (Delon-Martin et al. 1995;
Vaezy et al. 1997; Vaezy et al. 1999). Clinical treatments have targeted the eye
(Coleman et al. 1985), breast (Hynynen et al. 1996; Hynynen et al. 2001), kidney
(Vallancien et al. 1993), liver (ter Haar et al. 1998a), bladder (Vallancien et al. 1996),
and prostate (Bihrle 1985; Vallancien et al. 1992; Gelet et al. 1993; Madersbacher et
al. 1993; Foster et al. 1994; Sanghvi et al. 1996; Nakamura et al. 1997; Mulligan et al.
1997).
2.2. BIOEFFECTS OF ULTRASOUND
When tissue temperature is elevated (especially when induced artificially), the
condition is called hyperthermia. Ultrasound is able to induce hyperthermia because
the longitudinal propagating sound waves cause any particles in their path to begin to
oscillate. These oscillations cause density changes in the medium thru which the
sound is traveling. The medium resists the density change and energy is absorbed into
the medium in the form of heat. Different mediums are able resist this particle
oscillation to different degrees, which is quantified in a parameter called the
acoustical impedance. Acoustical impedance quantified as the product of sound
velocity and density of the material. As ultrasound travels from one material to
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another, the relative transmission and reflection at the interface are governed in part
by the acoustic impedances of the materials on each side of the interface. A large
difference in acoustic impedance will cause a greater fraction of the ultrasound to
reflect back into the material from which it came.
Recently man-made bubbles have been developed for bolus use as imaging contrast
agents. If ultrasonic sound waves hit bubbles at sufficient energy and frequency,
bubble diameter increases and decreases in a fashion inversely proportional to the
acoustic pressure, a process known as cavitation. This process absorbs more acoustic
energy than normal passage through tissues and can damage cells due to shear
stresses caused by microstreaming around the bubble. The resonance size of the
oscillating bubbles decreases with increasing frequency; at 1 MHz the resonance size
of an air bubble is 3.5pm in free fluid. Smaller bubbles will grow to resonance size by
rectified diffusion. When acoustic intensity is increased, inertial cavitation rather than
stable cavitation occurs. In the transient state, bubbles expand and then rapidly
contract and implode. This causes local pressures exceeding thousands of
atmospheres, temperatures in the thousands Kelvin and the formation of free radicals
(Flynn 1982). The pressure and temperature within the collapsing bubble hydrolyze
water vapor within the bubble, producing free radicals (Makino et al. 1983). Bubble
collapse also generates shock waves and shear forces within the medium that may
cause high velocity fluid jets capable of puncturing surrounding structures (Blake et
al. 1986; Zhang et al. 1993; Zhang and Duncan 1994; Sato et al. 1994; Krasovitski
and Kimmel 2001; Chahine 1982; Vogel et al. 1989; Kodama and Takayama 1998).
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2.3. MODES OF ULTRASOUND
Ultrasound is created using piezoelectric materials that convert (or transduce)
electrical energy into vibration. In the 1880s, Jacques and Pierre Currie found that
this is a result of the anisotropic structure of the material, because the lattice structure
that makes up piezoelectric material does not have a center of electrical symmetry.
When an electric charge is introduced across the crystal the particles expand or
contract (depending on the charge configuration) until elastic forces between the
particles counteract the electric forces (Mason 1950; Richardson 1962).
Therapeutic ultrasound is commonly delivered in three different modalities: shock
wave, continuous wave and pulsed continuous wave. The modalities are distinguished
by the different electrical signals through an ultrasonic transducer that produces them
as well as the bioeffects resulting from treatment.
Sending a voltage spike into an ultrasonic transducer produces a shockwave. These
signals are generally of very short duration (~-5ps) and high amplitude. Shockwaves
are most often used clinically in lithotripsy of kidney stones and gallstones and
stimulation of bone growth and tendon healing. The mechanism at work in these
therapies is widely believed to be cavitation as the pulses are too short for any
significant heating to occur.
Sending only a single frequency electrical input through an ultrasonic transducer
produces continuous wave ultrasound. CW ultrasound is both historically and most
often used clinically for various types of hyperthermia treatments. Pulsing continuous
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wave ultrasound, which separates segments of continuous wave ultrasound with
periods of time where no signal is inputted, can be used to cause cavitation with
minimal heating.
2.4. ULTRASONIC CONTRAST AGENT
Ultrasonic contrast agents (USCAs) were first developed in the 1960s, but only in the
last decade have they been available for use in humans. Most commonly, USCAs are
microbubbles filled with gas such as air or perfluorocarbon stabilized by external
shells made of galactose, albumin, lipids, or polymers. These shells slow the
degradation of microbubbles in the bloodstream, thus allowing contrast agents to be
injected systemically. Correas et al. in their 2001 review of ultrasonic contrast agents
defined USCAs as "an exogenous substance...administered, either in the blood pool
or in a cavity, to enhance ultrasonic signals." How the signals are enhanced depends
on local acoustic power (Powers 1997). Depending on the output power of the
ultrasound system, the ultrasonic frequency and the attenuation of the ultrasonic
signal, USCAs act as cavitation nuclei for either stable or inertial/transient cavitation.
This ability to cause cavitation events may be why multiple studies have shown that
several brands of USCAs enhance gene therapy uptake both in vitro and in vivo. Li et
al. (2003) performed an in vivo study in rat muscles comparing the gene efficiency
increase using ultrasound and each of the three commercially available USCAs:
Optison (human albumin; Nycomed-Amersham, Oslo, Norway), Levovist (SH U
508A; Schering, Berlin, Germany), and Albunex (Molecular Biosystems, San Diego,
CA). They found Optison, which is filled with perfluorocarbon and covered with a
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shell made of human albumin, increased gene expression more than its air-filled
competitors. They hypothesized this may be because Optison is more stable in the
bloodstream so there may be a higher bubble concentration at the cavitation site
during sonication. The next section of this paper covers the history of ultrasound-
mediated gene transfer (USMGT) in more detail.
3. COMBINING GENE THERAPY AND ULTRASOUND
3.1. CAVITATION EXPERIMENTS
Fechheimer et al in 1987 was the first to use ultrasound to transfect mammalian cells
with plasmid DNA using a method called sonication loading. The mechanism by
which the procedure worked was not explored in the article, although the process was
described as "gentle" to the cells. Wasan et al. used ultrasound in conjunction with
gene therapy in 1996 when it was observed that liposomes carrying DNA had a
tendency to form large complexes (Wasan et al. 1996). Ultrasound was used to break
up these complexes into uniform size. During this experiment, it was shown that the
liposomes protect the plasmid DNA from destruction by ultrasound-induced
cavitations.
Also in 1996, Kim et al compared 1 and 3.5 MHz continuous wave ultrasound against
pulsing wave ultrasound in vitro on primary fibroblasts, using variable sonication
times and pressures. By using f-galactose to calculate transient expression and
pMClneo poly(A) to calculate stable expression, they found the most efficient stable
transfection rates using 30 sec, 4 MPa continuous wave. With those settings a
transfection rate of 0.34% of the surviving cells was measured. Transient transfection
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rates were maximized to 2.4% using 60 sec, 3 MPa continuous wave sonications. In
both instances the survival rate for the cells was 50% (Kim et al. 1996). The authors
believed the mechanism of increased transfection was stable cavitation.
Greenleaf et al. first used cavitation bubbles in 1998 to increase transfection. A linear
relationship was found between transfection efficiency and average peak ultrasound
pressure (threshold 0.12MPa) with the peak transfection rate being 50%. They
hypothesized that bubbles violently collapse (transient cavitation) in first second of
sonication and permeabilize the cell.
Shockwave versus pulsed continuous wave sonications were compared by Huber et al
(1999) in HeLa cells using -galactosidase and luciferase plasmid DNA reporter. The
various modalities used were 60-360 shockwave pulses at 1Hz at magnitudes of 13,
16 and 19 kV, and 1.18MHz pulsed continuous wave with a 40% duty cycle and
pulse frequencies ranging from 1 to 500Hz. The optimal shockwave modality was
shown to have 0.08% efficiency (8 times greater than DNA alone) and 5% cell
viability while sinusoidal sonications were shown to have 3% efficiency (80 times
greater than DNA alone) with 45% cell viability.
Studies using ultrasound to facilitate gene therapy delivery in vivo have also been
performed. MR-guided focused ultrasound was used to direct delivery of plasmid
DNA into the thigh of an anesthetized rabbit (Bednarski et al. 1997). The experiment
showed a high level of transfection in the muscle parenchyma of the sonicated rabbit
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thigh and a much lower level in the control animal's muscle, although these results
may be partially explained by the experimental setup and the known ability of
ultrasound to disrupt endothelial barriers. Most other in vivo studies have involved the
cardiovascular system, either myocardium or vasculature. Taniyama et al. reported
that using ultrasound and microbubbles with naked plasmid wild type p53 gene
injection significantly decreased restenosis compared to controls in blood vessels
after balloon angioplasty injury (Taniyama et al. 2002b). Ultrasound was also used to
increase angiogenic gene expression delivered with naked DNA injection in ischemic
pig myocardium, although in this case no microbubbles were used (Schratzberger
2001).
But the big question still remains, how does ultrasound work with contrast agent to
increase uptake of gene therapy drugs? Taniyama et al. recently showed that plasmid
DNA could be delivered in clinically significant doses using ultrasound and the contrast
agent Optison with no apparent toxicity and speculated on the mechanism of increased
gene therapy transfection efficiency (Taniyama et al. 2002a). They believe the
ultrasound causes transient holes in the cell membrane. Another mechanism that has
been brought forth for this increased transfection rate is that the experimental
conditions are causing a type of cavitation where the microbubbles begin to vibrate,
getting bigger and smaller, instead of exploding. The vibration action causes reversible
mechanical stress on the cells, facilitating diffusion of the gene therapy into the cells.
Although these studies clearly demonstrate the feasibility of enhancing transfection
efficiency using ultrasound, there is little information about the local ultrasound
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conditions (frequency, power density, etc), and little understanding of the physical
mechanism(s) responsible for enhanced efficiency.
3.2. HEAT SHOCK PROTEIN EXPERIMENTS
Ultrasound has also been explored as a non-invasive heat source to use for activation
of a gene therapy/heat shock protein promoter complex. It has been suggested that
heat shock proteins (hsp) promoters could be used to spatially and temporally control
gene therapy delivery (Madio et al. 1998; Arai et al. 1999; Brade et al. 2000; Braiden
et al. 2000; Huang et al. 2000; Lohr et al. 2000; Vekris et al. 2000; Borrelli et al.
2001). Heat shock proteins, also called stress proteins, are a group of proteins that are
expressed when a cell undergoes various types of environmental stresses like heat,
cold and oxygen deprivation. This induction is controlled by the activation of the
gene promoter by mechanisms that are not completely understood. The well-
characterized hsp70B promoter has been shown to be activated mainly through
heating and is useful due to the magnitude of difference between induced protein
expression versus the basal expression. Previous work using hsp promoter gene
therapy constructs has shown that in vitro gene expression increased linearly with
heating duration after reaching a threshold temperature (Smith et al. 2002). Borrelli et
al. (2001) also demonstrated significant induction in vitro after exposure to
temperatures greater than 40*C and the magnitude of the induction increased from 41
to 43'C and varied with the duration of heating. Others have obtained similar results
(Brade et al. 2000; Gerner et al. 2000; Vekris et al. 2000) in vitro using higher
temperatures, up to 48*C, with reduced exposure times of 30 to 180 seconds.
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This methodology could be especially useful in delivering cytotoxic genes to
malignant tumors, where concern about gene expression in non-targeted areas is
paramount. Hsp70B-mediated gene therapy has been used in vivo for the expression
of a cytotoxic transgene to reduce tumor size in animal models of melanoma, breast
cancer, and glioma (Braiden et al. 2000; Huang et al. 2000; Lohr et al. 2000; Vekris et
al. 2000). Smith et al. (2002) have shown the utility of this system for targeted
induction using an adenovirus containing the cytotoxic Fas ligand gene under the
control of the hsp70B promoter. In that study the systemic delivery of the Fas ligand
adenoviral construct did not lead to liver toxicity unless the animals were exposed to
ultrasound-mediated hyperthermia. Ultrasound-induced hyperthermia is an optimal
choice for inducing gene expression because of short heating times, the ability to heat
deep tissue non-invasively, and its compatibility with MRI temperature monitoring.
Previous gene therapy experiments making use of this ultrasonic heating
methodology were able to show heat-induced gene expression in both rats, after a 3




In the following chapters, we seek to determine both the methodology in which
therapeutic focused ultrasound can be used to increase gene therapy uptake and some
of the risks associated with using ultrasound in this manner.
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To begin, we sought to test the effect of focused ultrasound with albumin-coated
microbubbles on an in vivo myocardial gene transfer of a plasmid/reporter gene
construct using a large animal model.
4.2. MATERIALS AND METHODS
Five Yorkshire pigs were used in the feasibility experiments. Inhalation anesthesia
using Isofluorane 1-2% was followed by intramuscular injections of Telazol
(4.4mg/kg) and xylazine (2.2mg/kg) to cause general anesthesia and intravenous
application of lidocaine (100mg) and Ampicillin (1g) to prevent cardiac arrhythmias
and infection. A left thoracotomy exposing the lateral free wall of the left ventricle
was performed. Four areas on the exposed ventricle sized 1cm square and spaced 1
cm apart were marked using 5/0 prolene suture thread. Each area was treated in one
of the following ways: (a) 2mL intramyocardial injection via 30G needle of 500ug
naked DNA plasmid encoding P-galactosidase mixed in TE buffer, (b) 2mL
intramyocardial injection via 30G needle of 500ug naked DNA plasmid encoding p-
galactosidase mixed in TE buffer and subsequent ultrasound application as described
below, (c) 2mL intramyocardial injection via 30G needle of 500ug naked DNA
plasmid encoding p-galactosidase and 0.3 mL albumin-coated microbubbles
(Optison, Mallinckrodt Inc; St Louis, MO) mixed in TE buffer and subsequent
ultrasound application as described below, or (d) 2 mL of TE buffer solution.
The ultrasound application was generated with a spherically curved air-backed piezo-
electric transducer with a 7 cm diameter, a 7 cm radius of curvature and a resonant
frequency of 0.891 MHz resulting in a focal width of approximately 2.5 mm and a
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focal length of 12 mm. The acoustic pressure was measured in water using a
hydrophone (Sonic Industries, Hatboro, PA). The peak pressure amplitude was 0.75
MPa, with a time average power of 1.26 W. The sonication time was 1 minute,
consisting of a 50ms sinusoidal burst every Is (5% duty cycle). The transducer was
fixed inside a cone-shaped applicator (built in-house) to ease targeting of the
ultrasound field that was filled with degassed water to increase ultrasonic coupling
(Figure 4.1). The outside of the flexible coupling surface was coated with sterile
ultrasound gel (Aquasonic 100; Parker, Orange, NJ) for the same purpose.
After each of the four areas was treated, the thoracotomy was closed and the animals
recovered over the next 72 hours. Euthanasia was performed by intra-cardiac
injection of potassium chloride after general aesthetic was given. The hearts were
harvested, and the marked areas were sectioned and flash frozen in liquid nitrogen.
Plezo-electric
Arbitrary Waveform ultrasound
Function Generator _P transducer
Water-filled Flexible
directing cone couplingsurface
Figure 4.1: Experimental set-up. An arbitrary waveform generator emitted 50ms
bursts of 0.891 MHz sinusoidal electrical energy every second. This energy was
amplified and then transformed to ultrasound by the transducer. The ultrasound was
focused through the water and into the tissue.
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An initial experiment in one animal was performed using the same protocol as above
to determine an appropriate power level to use in the experiments. Each of the four
areas of the heart was injected with 0.3 mL albumin-coated microbubbles mixed in
2mL TE buffer via a 30G needle. Each area was then exposed to ultrasound of
increasing power: OW (as a control), 1.86 W time average power (peak pressure 4.8
MPa), 2.68 W time average power (peak pressure 5.7 MPa) and 3.68 W time average
power (peak pressure 6.7 MPa). Twenty-four hours after exposure, the animal was
sacrificed and the myocardium was sectioned and flash frozen in liquid nitrogen.
The frozen sections were ground to powder and tissue debris was pelleted by
centrifugation at 14000g. Cell lysates were prepared using lysis buffer and p-
galactosidase protein concentration was quantified using an ELISA (Boehringer
Manheim, Manheim, Germany) according to manufacturer's instructions. Total
protein concentration was determined using the Bradford assay (Biorad Laboratories,
Richmond CA). Absorbance values were quantitated using an ELISA plate reader at a
wavelength of 405nm. Gene expression was quantified as the amount of [-
galactosidase relative to the total protein amount. All tissue samples were measured
in duplicate. A paired t-test was used to compare means and all analyses were
performed using the Sigma Stat software program (SPSS Inc, Chicago IL) with p
values < 0.05 considered significant.
4.3. RESULTS
The damage to myocardium after exposure to increasing focused ultrasound power
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Figure 4.2: Myocardial secdions of areas exposed to increasing ultrasonic power; (a)
0W - control, (b) 1.86 W time average power (peak pressure 4.8 MPa), (c) 2.68 W time
average power (peak pressure 5.7 MPa) and (d) 3.68 W time average power (peak
pressure 6.7 MPa). Damage ranges from local hemorrhage at the lowest power to
necrosis at the highest power.
was examined to determine the power level to be used in this experiment (Figure 4.2).
The lowest power (1.88W) reveals only focal hemorrhage with no myocyte necrosis,
while the 2.71W setting shows moderate hemorrhage with focal areas of necrosis. At
3.68W, there was marked hemorrhage with confluent zones of necrosis up to 0.5cm.
The hemorrhage and necrosis was most pronounced in the middle of the ventricular
wall, where the ultrasound power was focused. Based on these results, a time average
power level of 1.26 W (peak pressure 1.6 MPa) was chosen for the subsequent
experiments involving injection of genes.
B-galactosidase expression, as measured 24 hours after injection and sonciation, was
statistically different only between territories with plasmid alone and territories
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Figure 4.2: fi-galactosidase expression, as measured 24 hours after injection and
sonication, in areas injected with plasmid alone, injected with plasmid and then
exposed to ultrasound, and injected with plasmid and contrast agent and then
exposed to ultrasound.
exposed to plasmid, microbubbles and ultrasound (Figure 4.3). The mean beta-
galactosidase concentration in the plasmid-alone treatment territory was 1301 pg/mg
total protein versus 2451 pg/mg total protein in the ultrasound, microbubbles and
plasmid; a 88% increase (p = 0.044). In territories that had ultrasound exposure
without microbubbles, the mean was 1.5 fold higher than plasmid alone (2038 pg/mg
total protein); however this was not statistically significant. No beta-gal expression
was found in control injection territories.
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4.4. DISCUSSION
Our first study confirms the ability of using focused ultrasound with microbubbles to
increase gene therapy uptake in a plasmid construct. In the areas that were injected
with plasmid and microbubbles before being treated with focused ultrasound, a
statistically significant 88% increase was found over plasmid alone. This result agrees
with a previous in vivo study in which focused ultrasound and microbubbles were
found to increase the gene uptake of an adenoviral gene therapy construct 2-fold
(Shohet et al. 2000). Based on the pathology of the porcine myocardium after
ultrasound exposure, there should be little to no necrosis, although localized
hemorrhage should be expected. The increase in efficiency using contrast agent and
ultrasound was not as high as other reports previously published, which found as
much as a 20-fold increase in gene expression (Schratzberger et al. 2002). Differences
are to be expected since experiments differ in gene type, animal model, cell type, and
measurement methodology. However, differences could also be directly attributed to
the lack of knowledge of optimal ultrasound parameters. To date, there has not been a
published study that characterizes the optimal ultrasound frequency, modality, timing
and power for most effective gene transfer in vivo. Two recent papers have started
this process. Pislaru et al (2003) compared diagnostic versus continuous wave
ultrasound in gene transfer in rat muscle and found gene expression almost doubled
using the diagnostic imager. However, this was using only a single frequency and
power, and pulsed continuous wave was not compared. Chen et al. (2003) examined
the optimal modality, frequency, and power parameters using a diagnostic ultrasound
scanner only, and found that using pulsed wave versus continuous wave ultrasound
increased gene expression in rat myocardium significantly in vivo. Increased gene
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expression was also found with increasing power and decreasing frequency, with the
lowest frequency tested being 1.3 MHz. A similar systematic study characterizing the
optimal parameters for continuous wave and pulsed continuous wave will be
invaluable to decisions about the ability of to use ultrasound mediated gene transfer to
replace viral vectors without sacrificing transfer efficiency or if instead ultrasound
will be a helper-vector used only in conjunction with viral vectors to increase
efficiency farther.
5. BUILDING AND TESTING AN OPTIMIZED TRANSDUCER
5.1. BUILDING A NEW TRANSDUCER
Using the experience of the first feasibility tests, the need to optimize experimental
conditions for invasive in vivo experiments taking into consideration optimal
transducer size, focal distance, and frequency generation was recognized as a
necessary step in the final design of a minimally invasive ultrasound system for gene
therapy delivery.
Size was the first factor considered. The large size of the transducer used in the
feasibility experiments described in chapter 4 was inconvenient as it limited our
choice of experimental model as well as being bulky and hard to use. The new
transducer was designed to again be an spherically curved air-backed piezoelectric
transducer but this time smaller, with only a 2 cm diameter.
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Figure 5.1: Construction schematic of a single element transducer and holder.
The electrically asymmetric piezoelectric transducer is wired and placed in a
Plexiglas holder designed to hold the transducer by the perimeter edge only as well
as maintaining an air backing to reflect backward ultrasound propagation. A cone
shaped water-bath is attached to the front to increase ease of experimental use.
By choosing a transducer with a resonant frequency of 1.33 MHz to be used as the
"low" frequency, the same transducer can be used to create the "high" frequency by
using the transducer's 5th harmonic at 7.379 MHz. This comparison will determine if
the future clinical system should be designed as an external non-invasive device or a
minimally invasive catheter device.
The transducer was constructed from a 2cm diameter spherically shaped piece of
piezoelectric material (Staveley Sensors Inc, East Hartford CT) with a 2 cm radius of
curvature. Piezoelectric materials, as discussed in Section 2.3, convert electrical
energy into mechanical energy as a result of the electrical asymmetry of the
crystalline structure. When an electric charge is introduced across the crystal the
particles expand and contract to counteract the electric forces (Hynynen, 1990). A 28-
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gauge coaxial cable (Belden, St. Louis MO) is wired to the crystal by soldering the
conducting wire to the convex side of the crystal and then flipping the ground wires
over to the concave side and soldering them into place. To ensure proper
conductivity, the ground wires are split and soldered onto the crystal in two places,
180 degrees apart.
The crystal is then placed in a plexiglass cylinder whose inner opening was milled to
the size of the transducer. Using VIL-SIL silicone (Rhodia Silicones VSI, Troy NY)
mixed to a ratio of 40:1 compound (Part A): hardener (Part B), the crystal is attached
to the Plexiglas cylinder only around the outer rim to allow the free-hanging crystal
maximal freedom of movement. The coaxial cable and the back disk are then attached
to the bottom of the cylinder with silicone to create a watertight seal. The resultant air
backing of the transducer holder is important because the ultrasound waves created by
the movement of piezoelectric materials are bi-directional. When the ultrasound
waves traveling backwards (i.e. away from the desired location) encounter the
crystal/air interface, the acoustical impedance mismatch causes nearly all the energy
to be reflected back into the crystal where it adds to the ultrasound signal moving in
the desired direction.
To facilitate the use of the transducer, a cone shaped water basin was attached to the
front of the holder. First, another piece of Plexiglas was milled into a 1 cm long cone
shape. The larger opening matched the size of the transducer holder, while the smaller
opening tapered down to a 1 cm diameter. The smaller opening was capped with
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acoustically translucent Mylar and the cone was attached to the transducer holder
with silicone, carefully avoiding the crystal. A hole drilled in the side of the
transducer allows for filling the water bath with degassed water and a small screw
seals the cone for use.
Finally, the transducer must be electrically matched to 50 Ohms to match the output
impedance of the driving amplifier system. This is accomplished through a first-order
LC circuit.
5.2. TESTING AND CHARACTERIZING THE TRANSDUCER
A transducer is fully characterized by performing efficiency tests and measuring the
pressure field around the focus. Characterizations were performed at the ls and 5th
harmonics.
Efficiency was computed as the percentage of acoustic power delivered over
electrical power inputted. Acoustic power was measured with a radiation force
system; where an ultrasound beam is directed towards a perfectly absorbing target
hung from a laboratory balance (AE 200, Mettler Toledo, Columbus, OH) (Stewart
1982; IEEE 1990). Pressure exertion of the ultrasonic wave on the target will cause
the balance to measure a change of mass and the following equation can be used to
calculate acoustic power (PA)
PA = Am* g * c(T)/ cos(9)
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where g is the gravitational constant, c(T) is the temperature dependant speed of
sound, and 0 accounts for the curvature of the transducer. Transmitted electrical
power was measured with a commercial power meter and a dual-directional coupler
(HP 438A, Agilent Technologies, Palo Alto, CA).
Table 5.1: Efficiency Measurements at the 1st, 3 rd and 51h harmonics.
First Harmonic 1.33 MHz
Voltage Electric Power Acoustic Power Standard Error Efficiency
(V) (W) (W) (W)
0.07 1.10 0.759 0.004 69%
0.08 1.43 0.983 0.001 69 %
0.09 1.83 1.27 0.003 69%
0.10 2.26 1.56 0.017 69%
0.11 2.77 1.89 0.002 68%
Average 69 %
Third Harmonic 4.421 MHz
Voltage Electric Power Acoustic Power Standard Error Efficiency
(V) (W) (W) (W)
0.07 0.955 0.675 0.005 71 %
0.08 1.24 0.869 0.010 70 %
0.09 1.57 1.10 0.007 70%
0.10 1.95 1.35 0.003 69%
0.11 2.36 1.63 0.004 69%
Average 70 %
Fifth Harmonic 7.379 MHz
Voltage Electric Power Acoustic Power Standard Error Efficiency
(V) (W) (W) (W)
0.07 0.883 0.387 0.002 44 %
0.08 1.15 0.505 0.004 44%
0.09 1.44 0.638 0.004 44%
0.10 1.79 0.783 0.002 44 %
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Results from the efficiency tests are shown in Table 5.1. At each harmonic frequency
the transducer was tested at a variety of driving voltage levels. The acoustic power
was calculated using the equation above and the efficiency at that voltage was
determined. The efficiencies are then averaged at each frequency. The average
efficiency for this transducer was 69%, 7 0%, and 44% at the first, third and fifth
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The ultrasound field was characterized using automated stepper-motor scans (VP
9000, Velmex, Bloomfield, NY) in a degassed water bath (Figure 5.2). The acoustic
intensity was sampled using a PVDF needle hydrophone (0.075 mm diameter,
Precision Acoustic, England) connected an oscilloscope. The relative intensity
measurement was obtained by measuring the peak amplitude of the hydrophone
output signal. Beam profile measurements were made in a raster pattern with the
transducer driven in pulsing continuous-wave mode. The measurement tank
dimensions (0.25 x 0.33 x 0.75 m) were much larger than the beam profile and the
tank walls were lined with absorbing rubber to minimize acoustic reflection and
standing wave effects.
6. EFFECTS OF ULTRASONIC GENE THERAPY
6.1. MOTIVATION
After characterizing the newly built transducer, the next step was an investigation that
would test not just the efficiency of getting marker genes into cells using ultrasound
and microbubbles, but also how an actual therapeutic gene therapy would work after
being delivered using ultrasound. The Heme Oxygenase-1 gene (HO-1) codes for an
oxidative stress enzyme, seen in many types of cells and tissues, thought to protect
cells from ischemia. After incorporating this gene into in vivo rat kidneys and
microbubbles, we deprive the kidneys of oxygen and compare the protective function
in kidneys that incorporated the gene due to an adeno-associated viral (AAV) vector
alone to those that incorporated the gene with a combination of AAV vector,
ultrasound and microbubbles.
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6.2. MATERIALS AND METHODS
6.2.1. ULTRASOUND EXPOSURE
In these experiments, the same 1.33 MHz transducer designed and tested above was
again used at the first harmonic. Twenty-six Wister rats were anesthetized, secured in
a dorsal recumbent position and incised down the midline. A kidney was pulled
forward with blunt forceps until completely exposed, the renal artery and veins
clamped and a catheter was inserted into the renal artery. The transducer was placed
over the exposed kidney and the sonication started; after 10 seconds, the injection
would be pushed in over a 15 second interval, and the sonication would continue for
the last 35 seconds; totaling 1 minute of ultrasound exposure time. The kidney was
then tucked back into proper position and the other kidney was exposed and the
procedure repeated. A time average power of 0.13 W (peak pressure 0.33 kPa) was
used for the sonication, a value reduced from the previous work due to visible
damage on the kidney at higher powers. For the same reason, the duty cycle was also
reduced to 2.5% of the 200ms burst period. The injection consisted of a solution of an
adeno-associated viral vector/gene construct (Harvard Gene Initiative, Boston MA)
mixed with buffer and Optison equaling 10% of the solution.
6.2.2. BILATERAL ISCHEMIA INDUCTION
Three months after the gene therapy was injected, bilateral renal ischemia was
induced. Animals were anesthetized and both renal pedicles (artery and vein) were
exposed using a midline incision and clamped for 30 minutes followed by 24 hour
reperfusion. Sham animals had an incision made and kept open for 30 minutes of
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waiting time without clamping the renal arteries. After ischemia or sham treatment,
the muscle layer incisions were sutured and the skin incisions closed. Saline solution
was supplied to the rats during and after surgery to prevent dehydration.
6.2.3. RENAL FUNCTION MEASUREMENTS
Acute renal failure (ARF) is characterized by rapid decline in glomerular filtration
rate (GFR), estimated using measurements of creatinine levels in the blood and in the
urine. Usually decreases in GFR, increases in plasma creatinine, and increases in
blood urea nitrogen are indications of deterioration of the kidney. One month after
bilateral clamping, the experimental and control rats were housed in metabolic cages
for collecting urine. Blood samples were also drawn at this time. The rats were then
sacrificed and the kidneys were removed and snap-frozen in liquid nitrogen and
stored at -80'C. A total of 26 animals survived to the end of the study; 7 receiving the
AAV/gene construct injection without ultrasound with subsequent bilateral clamping
on 4, 6 receiving the AAV/gene construct injection with ultrasound and Optison with
subsequent bilateral clamping on 4, 6 receiving a buffer injection with ultrasound and
Optison with subsequent bilateral clamping on 3, and 7 animals using a buffer
injection without ultrasound with 4 receiving subsequent bilateral clamping.
6.3. RESULTS
After the experiments were concluded, it was communicated to us that the gene
constructs used in this experiment were mistakenly made with the HO-1 gene in the
reverse configuration. Although the reverse-configured gene did seem to show a
protective function from ischemia, the reasons for this are unexplained. To simplify
results only the data from injections of the buffer solution will be discussed.
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Creatinine concentration in blood serum, elevation of which is an indicator of renal
failure, was measured (Figure 6.1) as milligrams of creatinine per deciliter blood over
24 hours. The mean creatinine concentration in each of the four experimental
conditions was as follows: in the animals treated with ultrasound, microbubbles and
buffer and then clamped to induce ischemia the creatinine concentration was
2.9±0.7mg/dL, while the animals treated with ultrasound, microbubbles and buffer
but not clamped had a mean of 0.3±0.lmg/dL. The group injected with buffer alone
and then clamped had a mean creatinine of 1.4±0.3mg/dL, while the animals injected
with buffer and not clamped had a mean creatinine of 0.4±0. lmg/dL.
Blood urea nitrogen (BUN) in the urine over 24 hours was also measured as another
indication of renal failure (Figure 6.1). The mean BUN concentration of the animals
treated with ultrasound, microbubbles and buffer after clamping was 74.7± 1.8mg/dL
while the animals treated with ultrasound, microbubbles and buffer that were not
clamped had a BUN concentration of 18.9±14.6mg/dL. The group injected with
buffer alone and clamped had a mean BUN of 56.3±1.4mg/dL versus 25.7±7.8mg/dL
in the unclamped group.
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Figure 6.1: Kidney function measurements 24 hours after bilateral clamping to
induce ischemia. Animals were previously subjected to ultrasound application to the
kidney with concurrent microbubble injection 4 weeks prior to the clamping. In both
measurements the animals exposed to ultrasound previously showed more functional















Despite not using the gene expression data from the experiments, important
information about the usability of this method of gene delivery for therapies meant to
protect against ischemia can be gleaned from this study. The animals that were not
subjected to bilateral clamping had normal levels of BUN and creatinine, while the
animals that were clamped bilaterally had significantly elevated levels, indicative of
renal failure presumably due to ischemic damage. Interestingly, the animals that were
subject to injections of microbubbles and ultrasound application had higher levels
BUN and creatinine, meaning that the ultrasound treatment seems to have
preconditioned the renal system for ischemic damage. This could be because the
known bioeffect of ultrasonic cavitation in which capillaries transiently collapse,
blocking oxygen delivery to the immediate area. This may be damaging kidney cells
enough that the cells are less able to withstand the later prolonged oxygen
deprivation, even though the initial damage is not functionally significant. A study
with careful optimization of the lowest power levels still able to increase transfection
efficiency is needed to evaluate if this effect is inevitable. If so, this may have
significant implications when using ultrasonic cavitation mediated gene transfer to
protect against ischemic damage, a major area of gene therapy research, or in areas
already prone toward ischemic damage.
7. SPATIAL CONTROL OF GENE THERAPY DELIVERY
7.1. MOTIVATION
In this study, ultrasound is examined for facilitation of gene therapy delivery in the
context of spatially controlling therapeutic protein production. By attaching the gene
of interest to a heat shock protein promoter before placing it in the vector construct
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the gene is prevented from being transcribed into RNA. The cell will not produce the
therapeutic protein until the cell is heated to the point that the hsp promoter allows
transcription of the gene of interest. Ultrasound can be utilized to heat the gene
minimally invasively or even non-invasively after delivery into the cells. In the
following experiment we attempt to restrict protein production to one lobe of the
canine prostate after injecting gene therapy to the entire prostate.
7.2. MATERIALS AND METHODS
7.2.1. DEVELOPMENT OF GENE VECTOR
Recombinant adenoviral vectors were generated by standard techniques using the
shuttle plasmid pACCMV-pLpA and pJM17 as described by Becker et al. (1994),
which uses recombination in 293 cells to generate a replication-defective serotype 5
adenovirus. In these constructs, an expression cassette containing a minimal human
hsp70B promoter and RNA leader sequences upstream of the transgene with a
3'rabbit P-globin splice site and poly-adenylation sequences replacing the CMV
promoter and SV40 polyadenylation signal sequences from pACCMV-pLpA, as
described previously by Smith et al. (2002). The viral construct (Ad-HSP-Luc)
contains the transgene, firefly luciferase, under transcriptional control of the hsp70B
promoter.
7.2.2. GENE TRANSFER INTO PROSTATE
Three beagles ranging in size from 13-17 kg were anesthetized using a mixture of
200mg of ketamine hydrochloride (Abbott Laboratories, North Chicago, IL) and 20
mg of sodium xylazine (Xyla-ject, Phoenix Pharmaceuticals, St. Joseph, MO) injected
intramuscularly. Using a transrectal ultrasound imager, the prostate was visualized
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and catheters were inserted either just below the rectum or through the abdomen and
into each lobe of the prostate. The purified virus was then injected into each lobe of
the prostate (1 ml of solution in each lobe, consisting of 1 x 10 9pfu in saline),
followed by a saline wash. The animals were then allowed to wake naturally and pain
was controlled using twice-daily 0.07mL/kg intramuscular injections of
buprenorphine hydrochloride (Buprenex, Reckitt Benckiser Pharmaceuticals Inc.,
Richmond, VA).
7.2.3. HEAT INDUCTION
48 hours after the virus injection, the animals were again anesthetized with the same
mixture of ketamine and xylamine; then intubated. Hydration was maintained with a
saline IV drip. The procedure was monitored with a 1.5 T clinical MRI unit (GE







u t unrvi matcing
wasp station 
a ..... . ....... J
w..pMR1 Conrol Penetration
WiECoto Panel
Figure 7.1: Experimental set-up for heat induction. A transrectal
ultrasound transducer surrounded by a water-filled latex membrane
was placed in the rectum of the animal. The sonication was driven by
an RF system while MRI and thermocouples monitored temperature.
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Figure 2: MR images of the transducer inserted into the rectum and
positioned next to the prostate. A latex membrane surrounding the
transducer is expanded using heated degassed water and covered with
ultrasound gel to remove air pockets between the transducer and rectum.
(a) Coronal image (fast spin echo T2 weighted image TRITE 2000/75ms,
echo train length 8, field of view 24 cm, number of excitations 2) (b) Axial
image (the magnitude offast spoiled gradient-echo imaging described in
text).
unfocused, 1.5MHz, air-backed transrectal transducer (Smith et al. 1999). The
transducer was made of four 120 degree sections of cylindrical PZT-8 material (lead
zirconate-titanate, EC-69, EDO, Salt Lake City, UT) with a length of 15mm. Each of
these pieces were placed along the primary axis of the transducer shaft and scored on
the inner electrode surface. This divided each piece of PZT into four individually
powered and controllable sections, creating a total of 16 independent channels. A
multi-channel RF driving system, constructed in-house (Daum et al. 1998), was used
to control power delivery (Figure 7.1).
The prostate was found through palpitation and MR imaging and thermocouples were
inserted into each lobe. MR imaging confirmed the correct positioning (Figure 7.2).
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The transducer was then inserted into the rectum and the latex membrane (Civco,
Kalona, IA) surrounding the transducer was then inflated to fit snugly against the
rectal wall using degassed water continually circulated at body temperature using a
heat exchanger and pump. Ultrasound coupling gel (Aquasonic 100; Parker, Orange,
NJ) was used to eliminate air pockets between the latex membrane and rectal wall. A
heating pad was placed around the animal to maintain its body temperature.
Temperature was monitored using both MR thermometry and four copper-constantan
thermocouples placed in each lobe of the prostate, between the rectal wall and the
heated balloon, and externally. The thermocouples were constructed in house of
50pm diameter copper and constantan wire (California Fine Wire Co., Grover Beach,
CA) connected by soldering. The wires were incased in a fused silica sleeve used to
guide the thermocouple through a catheter to the prostate. The bare junction extended
outside of the tubing approximately 5mm to minimize viscous heating artifacts (Fry
and Fry 1954, Hynynen and Edwards 1989). As the temperature changes at the solder
joint, a voltage is generated that can be measured and converted to temperature by a
commercially available thermocouple reader (TC1000, Sable Systems, Henderson,
NV).
MR thermometry was performed as described elsewhere (Smith et al. 1999). Briefly,
temperatures were measured by exploiting the temperature dependence of the proton-
resonant frequency (Ishihara et al. 1995). Changes in the proton-resonant frequency
were estimated by measuring changes in phase and dividing by 2w times the time in
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which the phase developed (the echo time of the image). A fast spoiled gradient-echo
sequence was used to acquire the phase maps (Chung et al. 1996). The following
parameters were used: 39.5/19.3 (repetition time msec/echo time msec); flip angle,
300; bandwidth, 3.57 kHz; field of view, 20 cm; section thickness, 5 mm; matrix size,
256 x 128; imaging time, 5.2 seconds. The temperature dependence of the proton-
resonant frequency shift was assumed to be 0.010 ppm/*C, the value used by Chen et
al. (2000) when monitoring experiments in the human prostate. A set of four axial
images were taken approximately every 40 seconds to average out noise, then
imaging was paused to allow a thermocouple measurement without MR interference,
and then the next set of four images were acquired.
By using only the ultrasound channels that lined up with the left lobe of the prostate,
we were able to limit the hyperthermia exposure to that area in 2 of the 3 dogs. RF
powers up to 70 W were used to heat and maintain the sonicated area at the desired
temperature. The procedure continued until the temperature of the left lobe was at or
above 42*C for 25 minutes, as measured by the thermocouple.
7.2.4. SACRIFICE
Animals were sacrificed 15-20 hours after the heating using a 0.13 ml/kg intravenous
injection of Euthasol (Delmarva Laboratories, Midlothian, VA, USA). The prostate




The prostate was sectioned by four axial cuts into five pieces, labeled 1-5 from most
superior to most inferior. Sections 1, 3 and 5 were ground with a mortar and pestle
under liquid nitrogen. The resulting powder was dissolved in Promega reporter lysis
buffer (Promega Corporation, Madison, WI) containing protease inhibitors and
assayed (2 jl) using the Promega luciferase assay reagent (100 gl). Light
measurements were made with a luminometer (Berthold Lumat LB9501, Nashua,
NH) over 10 seconds and measured as light units per microgram of protein. Protein
was measured using the bicinchoninic acid (BCA) method first described by Smith et
aL. (1985) (Pierce Chemical Co, Rockford, IL) with BSA as a standard.
Thermal dose was calculated from temperatures from the middle of each lobe in dogs
1 and 2 using the equation set forth by Sapareto and Dewey (Sapareto and Dewey
1984). This equation is used to equate the range of actual temperatures during the
experiment with an "equivalent" time at a reference temperature of 43*C that would
have the same cellular response.
7.3. RESULTS
The temperature progressions during the experiments in the left (treated) and right
(untreated) lobes of the animals' prostates are shown in Figure 7.3 alongside the
electrical power delivered. The temperature data from dogs 1 and 3 was extracted
from the thermocouples placed in the left and right lobes of the prostate during the
experiment. With the first dog, a temperature difference was maintained throughout
the experiment, with the left lobe measuring 42*C or greater for 29 minutes and the
right lobe measuring less than 42*C throughout the experiment. Note that power was
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continually increased to compensate for temperature decreases, likely due to
increased blood flow resulting from the homeostatic vasodilation response to heat. In
Dog 3, because of the small size of the prostate, it was not possible to limit heating to
only one lobe with the experimental set-up used. Thus, the left and right lobe
temperature measurements were equal to or greater than 42'C for 24 and 23 minutes,
respectively, during 35 minutes of heating.
In dog 2, the left thermocouple was dislodged mid-experiment, which necessitated the














0 20 40 60 80 0 10 20 30
Time (min) Time (min)
Figure 7.3: Temperature maps of the prostate lobes during heat induction in dog 1 and
dog 3. The left lobe temperatures are marked with a solid black line and the right lobe
temperatures are marked with a dashed black line. Temperature data is from
thermocouples placed in the middle of each lobe. The lower graph shows the RF power
delivered to the transducer at each point during the experiment.
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104 minute long experiment. The majority of heating occurred between 12 and 20
minutes, between 75 and 85 minutes and between 90 and 97 minutes into the
experiment. Figure 7.4 shows the temperature delineation of the left and right lobes
during the heating, as measured by MRI, in dog 2. Signal intensity increases with
temperature and the lower temperature in the right lobe of the prostate is clearly
distinguished from the higher temperature in the left lobe at 12 minutes and 79
minutes into the experiment.
Thermal dose was calculated using temperatures from the middle of each lobe using
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Figure 7.4: MRI temperature maps of Dog 2. (a) An MRI image (the magnitude of
fast spoiled gradient-echo imaging described in text) of Dog 2 before heat induction
with the prostate outlined in black. The next three images are temperature maps
(MR parameters described in text) of the same area at (b) 12, (c) 39 and (d) 79
minutes into the experiment. Note that signal intensity increases with temperature
and that the lower temperature of the upper (right) lobe of the prostate is clearly
delineated from the higher temperature of the bottom (left) lobe in (a) and (c).
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thermal dose of 29.7 minutes in the left lobe and less than 0.01 minutes in the right
lobe while dog 2 had a thermal dose of 71.9 minutes in the left lobe versus 3.7
minutes in the right lobe. The third dog received 27.1 equivalent heating minutes in
the left lobe and 22.3 minutes in the right.
The luciferase activity observed in each lobe of the prostate for the three animals is
shown in Figure 5. Dog 1 shows a 31-fold increase in activity in the left (treated)
versus the right (untreated) lobe, while dog 2 shows a 14-fold increase and dog 3


















Figure 7.5: Luciferase activity in the three animals, separated
into each lobe and the axial sections numbered 1, 3, and 5 from
superior to inferior. Dog 1 shows a 31-fold increase in activity
from the left to the right lobe, while dog 2 shows a 14-fold increase
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7.4. DISCUSSION
We have successfully used MRI-guided, ultrasound-induced hyperthermia to spatially
control gene expression in an animal model relatively close to human in size. The
luciferase expression in dogs one and two was 31 and 14-fold higher, respectively, in
the heated lobe versus the control lobe. Dog three, in which both lobes were heated,
showed no significant difference in luciferase expression between the lobes.
The temperatures in these experiments were monitored in two ways, by MRI
thermometry and by thermocouples inserted into the animal. In the clinic, MR would
be the preferred temperature monitoring method due to its non-invasive nature and for
its ability to allow continuous monitoring in multiple planes, allowing any unwanted
heating to be identified and corrected. There are limitations when using MR
thermometry (as reviewed by Quesson et al., 2000) since temperature measurement is
based on the changes in phase relative to an image acquired before heating, any
movement by the subject disrupts the alignment between the images and the
continuity of the temperature measurements is lost. Fortunately in a clinical situation
both the situations can be controlled either by pausing the experiment to regain
temperature integrity or by using MRI thermometry sequences less sensitive to
motion (Kuroda et al., 2000). In addition, blood flow in large vessels can also cause
artifacts in the MRI-derived temperature maps.
Smith et al (2002) showed that gene expression increased linearly with the duration of
heating. In this work, dog 1 received the longest duration of heating above 42*C and
the highest level of luciferase activity was observed in the left lobe of this animal. In
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contrast, both lobes of the dog 3 prostate and the left lobe of the dog 2 prostate were
heated above the 42*C threshold temperature for 4-5 minutes less and all had a
comparably lower level of luciferase activity than the left lobe of dog 1. Madio et al
(1998) examined intrinsic heat shock protein expression in vivo with MR-monitored
ultrasonic heating of the rat leg to temperatures ranging from 42-45'C for forty-five
minutes. They found that hsp70 expression increased from 3 to 67 fold compared to
unheated muscle tissue. This agrees well with the 14 and 31 fold induction of
luciferase expression reported in this paper, despite the difference in tissue type.
A point of considerable interest is whether the induction of the hsp promoter is simply
the result of reaching a threshold temperature or if the level of expression is related to
a more complicated relationship between heating duration and temperature, as has
been found in numerous hyperthermia experiments. It is interesting that comparable
levels of induction have been obtained in vitro by Borrelli et al. (2001) and Vekris et
aL. (2000) at temperatures ranging from 41*C for 4 hours to 48*C for 30 seconds,
conditions which result in thermal doses that are approximately equal. The small
number of animals in the current experiment does not allow any conclusions to be
drawn regarding this question, partially due to the pattern of heating in dog 2. In that
animal, the thirty minute long heat treatment was performed in two phases with
significant cooling between the phases. This discontinuity of heating may be
important since it has been shown in vitro that cells develop thermotolerance after
exposure to non-lethal heating that can inhibit heat shock protein induction after a
second heat treatment (Mizzen and Welch 1988, Li and Mak 1989). During ultrasonic
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heating, animals are periodically able to regain temperature homeostasis through
vasodilation, which increases blood circulation to the heated tissue to cool the area
(Lehmann and de Lateur 1990). When the power is increased to return to the
hyperthermic temperature range, periods of heating are interspersed between intervals
at lower temperatures. Although the time intervals are much shorter then those
generally used when investigating thermotolerance, the inability to correlate reporter
expression with thermal dose in this study suggests the possibility of thermotolerance.
Further studies are needed to determine how thermal dose and thermotolerance
function in determining the extent of transgene expression from the hsp70B promoter.
This preliminary study supports the concept that transgene constructs under control of
the hsp70B promoter can be used in conjunction with MRI-guided ultrasound heating
to spatially control gene expression. It should be noted that in the current study an
unfocused 16-element array was used which allows only limited control of the field
being heated. The next step is to utilize a focused transducer to determine the extent
of spatial resolution that can be achieved with ultrasound mediated control of gene
expression. More sophisticated phased array applicators could provide greater control
of temperature and volume (Hutchinson and Hynynen 1998), which would enhance
the utility of this method. In addition the mechanism of activation remains to be
resolved, an issue which can be addressed by varying thermal conditions and the
duration of treatment, to determine if a simple threshold temperature is the principal
factor in vivo, or if a more complicated relationship exists.
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8. FUTURE WORK
Ultrasound-mediated gene transfer has the ability to make gene therapy a clinical
reality. The increase in gene uptake and the spatial control demonstrated in this work
is crucial for allowing clinically significant dosage restricted to tissues desired for
expression. More work is needed to optimize the methodology of ultrasound mediated
gene transfer and understanding how USMGT will be used in conjunction with other
vectors. Future work should include optimization of ultrasonic parameters, including
a final determination of the best ultrasound modality. Optimization of contrast agents,
the decision to attach genes to contrast agents or not, and accompanying treatment
such as lidocaine or heat treatment will also need to be included into a final protocol
to deliver gene therapy. Most interesting is the possibility of combining the two
systems described in this work. Experiments can be designed combining ultrasonic
cavitation to increase gene uptake into cells with ultrasonic heating to spatially
control expression. In the brain, ultrasonic cavitation could be used first to open the
blood/brain barrier in a selected site and then to increase gene uptake. Ultrasonic
heating could then be used to precisely control gene expression.
In the course of the experimental work outlined above, work by other groups has
progressed in some of these goals. As mentioned in section 4.4, ultrasonic parameter
optimization studies have begun comparing diagnostic versus continuous wave
ultrasound (Pislaru et al. 2003) and by examining the optimal modality, frequency,
and power parameters using a diagnostic ultrasound scanner (Chen et al. 2003). There
has also been progress in trying to understand the mechanism behind the increase in
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gene expression in USMGT. Lawrie et al (2000) examined the effects of free radicals
on gene expression, as cavitation is known to increase free radical formation.
However, gene expression was statistically unchanged when the intensity of
ultrasound was reduced until free radical production, as measured by hydrogen
peroxide production, was no longer detectable. They conclude that the mechanism is
likely to be purely mechanical. However, Bekeredjian et aL. (2003) showed that when
an area was injected with microbubbles, sonicated, and then immediately infused with
plasmid solution, gene expression was consistent with areas of no ultrasound
exposure. This would suggest that any increase in cell membrane permeability occurs
only during the sonication, which is inconsistent with the theory that microstreaming
punches holes in the cell membrane. If ultrasound-induced cavitation increases the
"fluidity" of cell membranes rather then actually damaging it then you would expect
the permeability to end with the ultrasound application. Nokazi et aL. (2003) used
lidocaine and heat, both known to increase membrane fluidity, in conjunction with
USMGT in vitro and found that increased membrane fluidity did increase gene
expression. They also found that increasing dosages of lidocaine increased cell
viability, possibly by facilitating membrane repair of any shear stress damage that did
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